Biomarker ID | 626 |
PMID | 21482022 |
Year | 2011 |
Biomarker | fPSA |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | Bivariate Model: OR: 0.561 (95% CI: 0.339-0.928) |
Effect on Pathways | Pathways include:-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
Experiment | Prostate Cancer Vs Controls |
Type of Biomarker | Diagnostic |
Cohort | 268 patients were chosen for the study out of which 107 suffered from prostate cancer. |
Senstivity | NA |
Specificity | NA |
AUC | 0.60 (95% CI: 0.53–0.66) |
Accuracy | NA |
Level Of Significance | p=0.024 |
Method Used | Access2 Immunoassay System analyzer |
Clinical | No |
Remarks | real clinical setting of consecutive men with tPSA 2.0–10 ng/ml and negative digital rectal examination were included. Base Model included all the variables that showed a corrected p value (pc)≤0.25 in comparisons between groups |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | KLK3 |